SOURCE: Clearant, Inc.

January 24, 2008 17:55 ET

Clearant, Inc. Appoints Chairman of Advisory Board

LOS ANGELES, CA--(Marketwire - January 24, 2008) - Clearant, Inc. (OTCBB: CLRA) ("Clearant," "the Company), owner of the Clearant Process®, designed to substantially reduce all types of pathogens in biological products including HIV, today announced it has appointed prominent surgeon Philip A. Davidson, MD to the positions of Chief Medical Officer and Chairman of the Company's Scientific Advisory Board.

Dr. Davidson has practiced orthopedic surgery in the Tampa Bay area since 1993 and is a founder of Tampa Bay Orthopaedic Specialists. He is an official physician for the NFL, Arena Football League and Major League Baseball, having been dually appointed by both the management and player's associations. He has invented, designed and developed a wide array of surgical procedures, implants and devices. Dr. Davidson has been particularly recognized for his expertise in cartilage restoration and joint resurfacing, especially in the knee.

Dr. Davidson is a participant in the Company's nine-surgeon, multi-center study and has successfully been using Clearant Processed grafts for several years. The multi-center study examined Clearant Processed soft tissue grafts for ACL reconstructive surgery. The results, released in June 2006, demonstrated the Clearant Process method of terminal sterilization -- gamma irradiation (50kGy dose) under controlled conditions and following a treatment with radio-protective solution -- can virtually eliminate infection risks associated with tissue allografts while maintaining the pre-implantation biomechanical performance of the tissue.

"Dr. Davidson will be a tremendous asset to Clearant as we communicate the importance of our technology to improving the safety of human tissue grafts," said Jon Garfield, Clearant's Chief Executive Officer. "We are pleased to have Dr. Davidson lead what we hope will become the leading orthopedic advisory board among companies involved in the sterilization of functional tissue."

"In my experience, having tissue of the highest sterility while also retaining all of its biomechanical qualities is absolutely essential," Dr. Davidson said. "After years of related research and personally implementing the Clearant Process in my practice, I am pleased to increase my involvement with Clearant, which has the potential to be the highest standard of care in the tissue industry."

Dr. Davidson has a degree from Harvard University and a Doctor of Medicine with Honors in Research from Cornell University Medical College. He trained in Orthopedics at Baylor College of Medicine and in Sports Medicine at the Kerlan-Jobe Clinic in Los Angeles. In addition to his role as an expert neutral physician with Major League Baseball, the NFL and the Arena Football League he was appointed as an orthopedic expert for the State of Florida by the Governor. Since 1995, he has been a faculty member at the University of South Florida College of Medicine and currently serves as a consultant and director for several medical device companies.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process®, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company has distributed implants sterilized by the Clearant Process® directly to surgeons, hospitals and clinics since June 2006. In addition, Clearant licenses the Clearant Process®, and provides its patented sterilization services, to tissue banks and other biological products manufacturers. To date more than 8,000 patients have been successfully implanted with Clearant Process® sterile implants supplied by one of the Company's licensed partners. The Clearant Process®, unlike its various competitors, is applied in the final packaging and reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. For more information, please visit

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at

Contact Information

  • Contact:
    Clearant, Inc.
    Jon Garfield
    Chief Executive Officer